GlassScriptPhysician profile
Jarrod Anthony Carver
NPI 1083418628
$4,259.50
in general payments reported to CMS, 2019-2025
19 companies · $4,260 in 2025
The $4,260 reported for 2025 was more than what 98% of Psychiatric/Mental Health (Nurse Practitioner) providers received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $4,260.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,260.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,259.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $863.10 | 2025 | Spravato, Invega Sustenna, Invega Trinza |
| Neurocrine Biosciences, INC. | $549.14 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $457.83 | 2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Vanda Pharmaceuticals INC. | $411.39 | 2025 | Fanapt |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $333.12 | 2025 | Caplyta |
| Alkermes, INC. | $295.37 | 2025 | Aristada, Lybalvi |
| Luye Pharma (USA) LTD. | $281.56 | 2025 | Erzofri Extended-Release |
| Teva Pharmaceuticals USA, INC. | $229.37 | 2025 | Austedo Xr, Uzedy |
| Axsome Therapeutics, INC. | $172.07 | 2025 | Auvelity, Sunosi |
| Lundbeck LLC | $166.92 | 2025 | Rexulti |
| Abbvie INC. | $153.62 | 2025 | |
| Neuronetics, INC. | $145.70 | 2025 | Neurostar Tms Therapy System |
| Biogen, INC. | $57.20 | 2025 | Zurzuvae |
| Indivior INC. | $36.26 | 2025 | Sublocade |
| E.R. Squibb & Sons, L.L.C. | $33.63 | 2025 | Cobenfy |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $29.21 | 2025 | Trintellix |
| Avadel Cns Pharmaceuticals, LLC | $21.88 | 2025 | Lumryz |
| Collegium Pharmaceutical, INC. | $14.27 | 2025 | Jornay Pm |
| Corium, LLC | $7.86 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jarrod Carver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.